Shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) have received an average broker rating score of 1.50 (Buy) from the four brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and three have issued a strong buy rating on the company. Accelerate Diagnostics’ rating score has declined by 50% in the last 90 days as a result of various analysts’ ratings changes.

Brokerages have set a 12-month consensus price objective of $26.50 for the company and are forecasting that the company will post ($0.33) EPS for the current quarter, according to Zacks. Zacks has also assigned Accelerate Diagnostics an industry rank of 155 out of 265 based on the ratings given to related companies.

Several equities analysts have recently weighed in on the company. Zacks Investment Research downgraded Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. BTIG Research downgraded Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a report on Wednesday, December 13th. They noted that the move was a valuation call.

In other Accelerate Diagnostics news, Director Jack W. Schuler acquired 340,964 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The shares were bought at an average cost of $18.51 per share, with a total value of $6,311,243.64. Following the completion of the transaction, the director now directly owns 44,670 shares of the company’s stock, valued at approximately $826,841.70. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jack W. Schuler acquired 51,600 shares of the company’s stock in a transaction that occurred on Wednesday, October 11th. The shares were acquired at an average cost of $20.27 per share, for a total transaction of $1,045,932.00. The disclosure for this purchase can be found here. Insiders have purchased 981,667 shares of company stock worth $18,879,924 over the last ninety days. 50.00% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the business. Legal & General Group Plc boosted its position in Accelerate Diagnostics by 31.7% in the second quarter. Legal & General Group Plc now owns 6,748 shares of the medical research company’s stock worth $184,000 after purchasing an additional 1,625 shares during the last quarter. Quantbot Technologies LP purchased a new position in Accelerate Diagnostics in the second quarter worth about $228,000. UBS Asset Management Americas Inc. purchased a new position in Accelerate Diagnostics in the second quarter worth about $243,000. SG Americas Securities LLC boosted its position in Accelerate Diagnostics by 87.8% in the second quarter. SG Americas Securities LLC now owns 11,054 shares of the medical research company’s stock worth $302,000 after purchasing an additional 5,169 shares during the last quarter. Finally, Intl Fcstone Inc. purchased a new position in Accelerate Diagnostics in the second quarter worth about $322,000. 47.89% of the stock is currently owned by institutional investors and hedge funds.

Accelerate Diagnostics (NASDAQ:AXDX) opened at $28.50 on Monday. The stock has a market capitalization of $1,580.00, a price-to-earnings ratio of -23.75 and a beta of 2.18. Accelerate Diagnostics has a twelve month low of $16.75 and a twelve month high of $30.45.

COPYRIGHT VIOLATION NOTICE: “Accelerate Diagnostics Inc (AXDX) Given $26.50 Consensus Target Price by Analysts” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.watchlistnews.com/accelerate-diagnostics-inc-axdx-given-26-50-consensus-target-price-by-analysts/1798513.html.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Get a free copy of the Zacks research report on Accelerate Diagnostics (AXDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with Analyst Ratings Network's FREE daily email newsletter.